Dipesh Uprety, Assistant Professor of Thoracic Oncology at Karmanos Cancer Institute, shared a post on X about recent paper by Jacob Sands, Medical oncologist at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“TROPION-Lung05: a phase II trial.

Patients with advanced/metastatic NSCLC with actionable genomic alterations after disease progression on targeted therapy and chemotherapy received Dato-DXd.

ORR 35.8%, DCR 78.8%, Median DoR 7 months.”

“Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study”

Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares, et al.

Dipesh Uprety: TROPION-Lung05 - a phase II trial on NSCLC by Jacob Sands et al.

Dipesh Uprety: TROPION-Lung05 – a phase II trial on NSCLC by Jacob Sands et al.